Summary
The FDA has granted Priority Review to a first-in-class PI3K/mTOR inhibitor for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. This milestone signals a potential shift in second-line treatment options globally, including for patients in Malaysia.
|
This new antineoplastic agent Fast-Tracked Review: A Global Milestone with Local Relevance
In a major development for the global oncology community, the U.S. Food and Drug Administration (FDA) granted priority review to a new antineoplastic agent, a first-in-class PI3K/mTOR inhibitor, for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2–), PIK3CA wild-type advanced breast cancer. The Prescription Drug User Fee Act (PDUFA) action date is set for July 17, 2026, marking a pivotal regulatory milestone in the effort to deliver more effective, targeted cancer therapies.
While this breakthrough is happening in the U.S., it carries significant weight for countries like Malaysia. Onco Life Centre, a Malaysian leader in cancer care, is closely monitoring this progress. With Malaysian sites participating in global trials, the implications for local breast cancer patients could be profound.
Why this new antineoplastic agent is a Game-Changer for HR+/HER2– Breast Cancer
Addressing an Unmet Need in PIK3CA Wild-Type Patients
Globally, nearly 60–70% of HR+/HER2 metastatic breast cancers are PIK3CA wild-type. Historically, patients with wild-type tumors had limited treatment options after progressing on first-line CDK4/6 inhibitors and aromatase inhibitors, often relegated to hormonal therapy or chemotherapy, both of which offer modest progression-free survival (PFS).
This new antineoplastic agent’s application proposes its use in combination with hormonal therapy, with or without another targeted therapy drug , for this very population. This represents a significant treatment option to patients who have long lacked a tailored therapy.
Pivotal Milestone Backed by Strong Clinical Data
VIKTORIA-1 Phase 3 Trial Results
The FDA’s acceptance and assignment of a PDUFA date was supported by the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial. This open-label study compared two antineoplastic agents-based regimens to standard hormonal therapy.
- Triplet regimen :
- Median PFS: 9.3 months
- Control ( hormonal therapy alone): 2.0 months
- Hazard ratio (HR): 0.24; 76% risk reduction; P < .0001
- Doublet regimen :
- Median PFS: 7.4 months
- HR: 0.33; 67% risk reduction; P < .0001
The objective response rates (ORRs) were also much higher in the investigational arms: 32% (triplet) and 28.3% (doublet) vs. 1% in the control.
These results highlight this new antineoplastic agent’s potential as a new standard after CDK4/6 inhibitor failure, particularly for the underserved wild-type subgroup.
FDA’s Real-Time Oncology Review Program: Accelerating Access
This antineoplastic agent’s NDA was accepted under the FDA’s Real-Time Oncology Review (RTOR) pilot program, which is designed to expedite the review of oncology drugs that address high unmet needs. The drug had previously received Breakthrough Therapy Designation and Fast Track status, reflecting the urgency and potential impact of this therapy.
Celcuity, the company behind this new antineoplastic agent, emphasized that the “FDA’s acceptance” of the NDA and the “assignment of a PDUFA” date is a “pivotal milestone in our efforts to bring” this treatment to market.
Safety and Tolerability: A Manageable Profile
Despite its broad action on the PI3K/AKT/mTOR (PAM) pathway, this antineoplastic agent demonstrated a manageable safety profile:
- Low discontinuation rates: 2.3% (triplet), 3.1% (doublet)
- Common adverse events: stomatitis, hyperglycemia
- Severe hyperglycemia (Grade 3/4) was less frequent than with isoform-specific PI3K inhibitors
Experts attribute the favorable safety to gedatolisib’s comprehensive blockade of the PAM pathway, which helps avoid the adaptive feedback loops that often drive resistance.
This new antineoplastic agent’s Mechanism: A Comprehensive Inhibitor
Unlike earlier agents that target isolated nodes (such as mTORC1 or PI3K-alpha alone), this new antineoplastic agent inhibits all four Class I PI3K isoforms and mTORC1/2, providing a full pathway shutdown. This approach helps overcome endocrine resistance, which frequently limits the efficacy of standard hormonal therapies.
The inhibition enables full suppression of the PAM pathway by minimizing cancer cell survival mechanisms. This mechanism offers hope for longer disease control and better outcomes.
Looking Ahead: Will This New Antineoplastic Agent Become a Global Standard?
Celcuity’s success with the FDA will likely guide other regulatory decisions worldwide, including potential filings with the European Medicines Agency (EMA) and Malaysian NPRA. If approved, this could redefine second-line therapy for HR+/HER2–, PIK3CA wild-type breast cancer — replacing current modest treatments with a proven, targeted alternative.
The “trial Celc G-201”, along with VIKTORIA-1 and -2, lay the groundwork for a broad regulatory and clinical footprint.
The coming months leading up to July 17, 2026, will be critical. If the FDA approves this new antineoplastic agent, the global oncology landscape, including care in Malaysia, will shift toward a more targeted, effective, and tolerable treatment paradigm.
Join the Global Conversation
Stay updated with Onco Life Centre as we follow the journey of this new drug. We’ are committed to bringing innovative therapies to patients in Malaysia.
